BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231117T130000
DTEND;TZID=America/New_York:20231117T140000
DTSTAMP:20260404T092826
CREATED:20231025T210322Z
LAST-MODIFIED:20231025T210322Z
UID:45830-1700226000-1700229600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - An Informational Session from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Friday\, November 17\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nOVERVIEW:\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from HEM-POWR\, a multinational\,open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi®. \nThere will also be a review of the Q4 2023 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nMark T. Reding\, MD. \nDirector\, Center for Bleeding and Clotting Disorders\nProfessor of Medicine\, Division of Hematology\, Oncology\, and Transplantation\nUniversity of Minnesota \n\n\n\nFor additional important risk and use information\, please see the full Prescribing Information for Jivi.\nYou are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
URL:https://hemoalliance.org/alliance-events/an-informational-session-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR